Corient Private Wealth’s Bristol-Myers Squibb BMY Stock Holding History

Corient Private Wealth’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.7M	Buy	532,609 +86,788	+19%	+$4.98M	0.04%	318
2026 Q1	$26.9M	Sell	445,821 -43,527	-9%	-$2.54M	0.04%	340
2025 Q4	$26.4M	Buy	489,348 +33,958	+7%	+$1.63M	0.04%	345
2025 Q3	$20.5M	Sell	455,390 -57,056	-11%	-$2.66M	0.03%	385
2025 Q2	$23.7M	Sell	512,446 -22,382	-4%	-$1.1M	0.03%	360
2025 Q1	$32.6M	Sell	534,828 -77,840	-13%	-$4.54M	0.05%	299
2024 Q4	$34.7M	Sell	612,668 -14,839	-2%	-$829K	0.06%	283
2024 Q3	$32.5M	Sell	627,507 -38,977	-6%	-$1.83M	0.05%	317
2024 Q2	$27.7M	Sell	666,484 -113,062	-15%	-$5.06M	0.05%	325
2024 Q1	$42.3M	Buy	779,546 +2,694	+0.3%	+$137K	0.08%	253
2023 Q4	$39.9M	Sell	776,852 -338,967	-30%	-$17.8M	0.07%	258
2023 Q3	$64.8M	Buy	1,115,819 +26,714	+2%	+$1.64M	0.15%	157
2023 Q2	$69.6M	Buy	1,089,105 +215,140	+25%	+$14.4M	0.16%	144
2023 Q1	$60.5M	Buy	873,965 +276,587	+46%	+$19.5M	0.16%	141
2022 Q4	$43M	Buy	+597,378	New	+$45M	0.16%	150

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Corient Private Wealth's BMY Position: Q2 2026 in Review

Corient Private Wealth increased its Bristol-Myers Squibb (BMY) stake by 19% in Q2 2026, buying an estimated $4.98M and bringing the position to 532,609 shares worth $30.7M. The position accounts for 0.04% of the portfolio, ranked #318.

Corient Private Wealth first reported a position in BMY in Q4 2022 and has held it in 15 quarters since. The position peaked at $69.6M in Q2 2023. 2,521 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Corient Private Wealth held 532,609 shares of Bristol-Myers Squibb worth $30.7M as of Q2 2026.
Corient Private Wealth bought 86,788 Bristol-Myers Squibb shares in Q2 2026, an estimated $4.98M.
Bristol-Myers Squibb made up 0.04% of Corient Private Wealth's portfolio in Q2 2026, its #318 holding.
Corient Private Wealth first reported a position in Bristol-Myers Squibb in Q4 2022 and has held it in 15 quarters since.
Corient Private Wealth's Bristol-Myers Squibb position peaked at $69.6M in Q2 2023.
2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.